Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study

Fecha de publicación: 01/10/2020 Fecha Ahead of Print: 01/06/2020

Autores de IIS La Fe

Maria Amparo Mercado Pardo

Autor
Pablo Berrocal Gil

Autor
María José Pérez Durá

Autor

Participantes ajenos a IIS La Fe

Jacob, J
Miro, O
Ferre, C
Borraz-Ordas, C
Llopis-Garcia, G
Comabella, R
Fernandez-Canadas, JM
Roset, A
Richard-Espiga, F
Valero-Domenech, A
Martinez-Gimeno, JL
Martin-Sanchez, FJ
Llorens, P
Alvarez-Perez, JM
Lopez-Diez, P
Herrero-Puente, P
Comin-Colet, J

Grupos

Investigacion clínica en enfermedades crónicas e Infección por el VIH

Investigador establecido

Marta Montero Alonso

Abstract

Introduction The presence of iron deficiency (ID) in patients with acute heart failure (AHF) is high. There are few studies on the characteristics of these patients and the safety of ferric carboxymaltose administration (FCM). Objective Study the differences among patients with AHF based on the presence and type of ID as well as the safety of FCM administration in these patients. Method The AHF-ID study is a multicentre, analytical, prospective follow-up cohort including patients admitted to six Spanish hospitals for AHF. ID was defined as serum ferritin <100 mu g/L (group A) or ferritin 100-299 mu g/L with a TSAT <20% (group B). In cases receiving FCM the appearance of adverse events was analysed. Adjusted Cox regression was used to determine the association with 30-days reattendance for AHF after discharge. Results A total of 221 patients were recruited; 191 (86.4%) presented ID, 121 (63.4%) group A and 70 (36.6%) group B. There were scarce differences between the groups analysed. No differences were found in 30-days reattendance for AHF. FCM was administered to 158 (71.5%) patients, with 8 (5.1%) presenting adverse events, the most frequent being digestive alterations. Treatment was not discontinued in any case. Conclusions There are scarce differences between the presence and the type of ID in patients with AHF. The administration of FCM in patients with ID and AHF is safe.